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Abstract
Purpose The prognosis of patients with advanced and
recurrent urothelial cancer (UC) is poor. Although cisplatin
(CDDP)-containing chemotherapy is the most effective
regimen in these patients, there is no other established
chemotherapeutic regimen. We administered combination
therapy with low-dose gemcitabine (GEM) and paclitaxel
(PTX), named low-dose gemcitabine–paclitaxel (LD-GP)
therapy, as salvage therapy for these patients. The aim was
to evaluate the anti-tumoral effects, relief of pain, and
toxicity of LD-GP therapy in patients with resistance to
CDDP-containing therapy.
Patients and methods Thirty-five patients with advanced
UC, previously treated with CDDP-containing regimens,
were treated with LD-GP therapy (GEM, 700 mg/m2 ? PTX,
70 mg/m2 on day 1 and 8, repeated every 28 days). Pain was
measured on a visual analog scale before and after treatment.
Pain relief and survival were compared between this and other
treatment regimens.
Results None of the patients had complete response to
LD-GP therapy. Partial response and stable disease were
seen in 25.7 and 62.9 % of patients, respectively. Kaplan–
Meier curves showed better survival in patients with LD-
GP therapy than with others (p = 0.034). Twenty-eight
patients (80.0 %) had adequate pain relief, and only two
patients needed to increase their analgesics. Other regimens
demonstrated pain relief in 30.4 % of patients. Common
toxicities included leukopenia, with five patients requiring
granular colony-stimulating factor therapy (14.3 %). The
most common non-hematologic toxicity was fatigue
(n = 7, 17.1 %).
Conclusions LD-GP therapy is feasible and well tolerated
as salvage therapy in patients with advanced UC with
resistance to CDDP-containing therapy.
Keywords Urothelial cancer  Gemcitabine  Paclitaxel 
Toxicity  Pain relief
Introduction
Urothelial cancer (UC) has a high prevalence rate among
the elderly. Almost all UC patients with low-grade and
low-stage disease can be cured by definitive local therapy,
including transurethral resection (TUR). On the other hand,
unfortunately, nearly two-thirds of those with muscle
invasion subsequently show regional or systemic disease
recurrence. The prognosis of patients with unresectable and
metastatic UC is poor, with an average survival rate in
untreated patients of 3–6 months [1]. In addition, patients
with recurrence after radical cystectomy showed a 1- and
3-year survival of only 17 and 6 %, respectively [2].
Currently, systemic chemotherapy is the only therapeutic
modality that produces somewhat long-term survival in
these patients.
Cisplatin (CDDP) is one of the most commonly used
chemotherapeutic agents for patients with UC. Combined
chemotherapy with methotrexate, vinblastine, doxorubicin,
and CDDP (MVAC) has been the most common and useful
regimen for advanced UC since the 1980 s. However, a
large trial with long-term follow-up on MVAC showed a
progression-free survival rate at 6 years of only 3.7 % [3].
Furthermore, administration of MVAC to elderly patients
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presents many and varied problems and considerable
toxicity, including myelosuppression, nephrotoxicity, and
neuropathy. Recently, the combination of gemcitabine
(GEM) and CDDP (GC) has become another standard
regimen for advanced UC, because it has been shown to
have similar anti-tumoral effects and less toxicity com-
pared with MVAC [4]. However, this regimen has also
shown poor outcomes and survival on long-term follow-up,
particularly in patients with metastatic UC [3, 5]. Hence,
various drugs and regimens have been tried in patients with
advanced UC who were refractory to prior chemotherapy.
As mentioned above, CDDP is a key agent for first-line
chemotherapy. Hence, many investigators have studied use
of non-CDDP agents, such as GEM and paclitaxel (PTX),
as second- or third-line agents. Previous studies reported
minimal toxicity and an overall response rate of approxi-
mately 25 % with single-drug therapy with GEM in
patients with advanced bladder cancer, while PTX
administered as a single agent was reported as producing
an overall response rate of 42 % in bladder cancer [6, 7].
Thus, GEM and PTX are regarded as being useful and
effective agents for bladder cancer. However, these studies
were performed in patients with previously untreated UC.
In another report, response rates to single-agent therapy
with GEM and PTX were approximately 11 and 7 %,
respectively [8, 9]. Based on these facts, many urologists
and medical oncologists believe that the efficacy and
duration of anticancer effect of GEM and PTX, adminis-
tered as single agents, are short and insufficient in patients
with previous chemotherapy-refractory UC. To overcome
this, use of various regimens and schedules combining
GEM and PTX therapy (GP therapy) have been reported in
advanced UC patients with failure of CDDP-based regi-
mens [10–19]. However, the optimal schedule and dosage
of the combination as salvage chemotherapy after failure of
CDDP-containing chemotherapy is still controversial.
UC disease progression often results in development of
painful and debilitating masses in local and distant organs. In
fact, almost all patients with unresectable metastatic and/or
locally advanced UC require some kind of analgesic.
Although pain is the most devastating symptom of these
patients, pain relief is unsatisfactory in some of these patients
despite the use of morphine hydrochloride. In addition,
analgesics often induce unpleasant side effects and may
decrease the patients’ quality of life (QOL). Hence, pain
relief with minimal analgesic dosages is an important goal
for patients with advanced and recurrent UC. Several reports
have demonstrated that GEM and PTX improve pain relief in
a variety of cancers [8, 20]. On the other hand, there is little
information regarding pain relief with the use of combination
GP therapy in patients with advanced UC.
The aim of the present study was to evaluate the anti-
tumoral effects and toxicity of low-dose GP (LD-GP)
therapy in UC patients with resistance to CDDP-containing
therapy. In addition, we paid special attention to pain relief




This is a retrospective cohort study of 35 patients, 26 men
and nine women, with a median age of 68 years (inter-
quartile range, IQR = 65–77 years), treated with LD-GP
therapy for metastatic and/or recurrent UC, previously
treated with CDDP-containing chemotherapy at Nagasaki
University Hospital from 2003 to 2011. Histologic or
cytologic diagnosis of UC was established in all patients.
Patients’ characteristics are shown in Table 1. The tumor
originated in the upper urinary tract in 13, in the bladder in
22, and in both of them in 1 patient. Eighteen patients had
metastasis at the time of initial diagnosis, and 17 patients
showed metastasis and/or local recurrence despite previous
treatments. All patients received CDDP-based chemother-
apy before this therapy and developed progression after
undergoing CDDP-based chemotherapy. All patients were
required to have a World Health Organization (WHO)
performance status (PS) of 0, 1, or 2. The median (IQR)
follow-up period was 10 months (4–19 months).
As a control group, we evaluated 23 patients who
received other treatment regimens (GEM alone, n = 7; PTX
alone, n = 2; PTX ? carboplatin, n = 9; GEM ? carbo-
platin, n = 2; and GEM ? CDDP, n = 3) during the same
period. The clinical features and previous treatments of these
patients are shown in Table 1. Although this selection was not
randomized, there were no statistical differences in patient
characteristics between these two groups. In this study, all 58
patients were diagnosed as UC by histological examination.
However, squamous cell carcinoma (SCC) and adenocarci-
noma were detected in four and two specimens, respectively.
Among these 6 patients, 3 patients with SCC and the 2
patients with adenocarcinoma were treated with LD-GP
therapy, while 1 patient with adenocarcinoma was treated
with a different therapeutic regimen (GEM ? carboplatin).
Regimen
The GP regimen used in this study was as follows: GEM was
administered at a dose of 700 mg/m2 intravenously for
30 min on day 1 and 8 of each 28-day cycle. Paclitaxel was
administrated at a dose of 70 mg/m2 intravenously over 3 h
on day 1 and 8 of each 28-day cycle. Dexamethasone sodium
phosphate (6.6 mg), diphenhydramine hydrochloride (50 mg),
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and ranitidine hydrochloride (100 mg) were administered
before treatment.
In total, 237 cycles were administered. Thirty-three
patients (94.3 %) received at least two cycles of LD-GP
therapy. Of the two patients who received less than two
cycles, one patient had rapid tumor progression and
the other had severe toxicity (leukopenia). Patients
received a median of five treatment cycles (IQR = 2–9,
range = 1–43). Between 10 and 16 weeks after GP ther-
apy, all patients underwent a computed tomography (CT)
scan and/or magnetic resonance imaging (MRI) to deter-
mine the in-field tumor response. The local response was
assessed using the Response Evaluation Criteria in Solid
Tumors guideline version 1.1. [21]. Based on the guide-
lines, complete response (CR) was defined as the disap-
pearance of all target lesions and reduction of any
pathological lymph nodes to \10 mm in the short axis.
Partial response (PR) was defined as a decrease in the sum
of the longest tumor diameters by at least 30 %. Stable
disease (SD) was defined as neither sufficient shrinkage to
qualify as PR nor sufficient increase in size to qualify as
progressive disease (PD), which was defined as an increase
in the sum of the longest tumor diameters by at least 20 %.
In addition to the relative increase of 20 %, the sum had to
also demonstrate an absolute increase of at least 5 mm. The
appearance of new lesion(s) was also considered disease
progression.
In this study, almost all (34 of 35, 97.1 %, and 33 of 35,
94.2 %, respectively) of the planned GEM (700 mg/m2)
and PTX (70 mg/m2) doses were administered on day 1
and 8 of each cycle. In two patients with severe toxicities,
dosages of GEM and PTX were decreased to 600 mg/m2
and 60 mg/m2, respectively, ensuring continuation of the
therapy. The study protocol was approved by the Institu-
tional Review Board of Nagasaki University Hospital, and
all patients provided written informed consent.
Evaluation of pain relief and adverse events
Since pain is the most important symptom of advanced
cancer, the clinical benefit of the treatment was measured
by rating pain on a visual analog scale (VAS) of 0–10
(0 indicating no pain and 10 being the most severe pain
imaginable). VAS scores were assessed one to 3 days prior
to initiating GP therapy and 6–12 weeks after starting the
therapy. Positive pain relief was defined as a decrease in
analgesic consumption or a decrease in VAS scores without
increasing the dose of analgesics. Regulation of analgesic
dose, including nonsteroidal anti-inflammatory drugs
(NSAIDs) and opioids, was performed by an independent
team who were unaware of the study.
Acute toxicities were graded using the Common Tox-
icity Criteria of the National Cancer Institute (version 3.0).
Toxicity was assessed in all patients who received GP.
Statistical analysis
The primary endpoint of the study was to evaluate pain
relief and adverse events after LD-GP therapy. In addition,
anti-tumoral effects, including survival rates and duration,
were also investigated. Overall survival was measured
from the first day of salvage chemotherapy to the day of
patient death or last patient contact. Survivals were dem-
onstrated and analyzed using Kaplan–Meier curves and the
log-rank P test. All patients enrolled in the trial were
included in the analyses.
Data are expressed as median (IQR). The Mann–Whitney
U test was used for analysis of continuous variables. The chi-
square test and Fisher’s exact test were used for categorical
comparison of the data. All statistical tests were two-sided,
and significance was defined as p \ 0.05. All statistical
analyses were performed on a personal computer with the
statistical package StatView for Windows (version 5.0,
Abacus Concept, Inc., Berkeley, CA).










Interquartile range 65–77 60–75
Sex (%) 0.159
Male 26 (74.3) 13 (56.5)
Female 9 (25.7) 10 (43.5)
Performance status 0.439
0 14 (40.0) 13 (56.5)
1 16 (45.7) 7 (30.4)
2 5 (14.3) 3 (13.0)
Site of primary tumor (%) 0.837
Upper urinary tract 13 (37.1) 10 (43.5)
Bladder 21 (60.0) 12 (52.2)
Both 1 (2.9) 1 (4.3)
Prior treatment (%) 0.110
Chem 8 (22.9) 3 (13.0)
Chem ? Ope 17 (48.6) 12 (52.2)
Chem ? Rad 6 (17.1) 4 (17.4)
Chem ? Ope ? Rad 4 (11.4) 4 (17.4)
Second-/third-line (%) 0.347
Second-line therapy 31 (88.6) 22 (95.7)
Third-line therapy 4 (11.4) 1 (4.3)
LD-GP low-dose combined therapy of gemcitabine and paclitaxel,
Chem chemotherapy, OP operation, Rad radiation




The anti-tumor effects of LD-GP therapy and other regi-
mens on measurable solid masses are shown in Table 2.
None of the 35 patients who received LD-GP therapy had
CR, although nine patients (25.7 %) had PR. PD, on the
other hand, was seen in four patients (11.4 %), while 22
patients (62.9 %) had SD. Thus, the major response rate
(CR ? PR) and disease control rate (CR ? PR ? SD)
were 25.7 % and 88.6 %, respectively. Major response
rates and disease control rates in the other regimens group
were 17.3 and 73.9 %, respectively. Thus, there were no
significant differences in major response rates between the
two groups (p = 0.220). Kaplan–Meier survival curves are
shown in Fig. 1. Median survival rate of patients in the LD-
GP therapy group was 12 months (IQR = 6–22 months).
With regard to the relationship between survival and PS,
median survival (IQR) was 9 months (7–16 months) in
patients with a PS of 0, 10 months (6–15 months) in those
with a PS of 1, and 5 months (3–12 months) in those with a
PS of 2. The 1- and 2-year survival rates after LD-GP
therapy were 58.1 and 32.9 %, respectively. On the other
hand, median survival and 1- and 2-year survival rates in
the other regimens group were 9 months and 44.6 and
8.4 %, respectively. Thus, the survival of patients who
received the LD-GP regimen was significantly better than
that of those who received other treatment regimens (log-
rank p = 0.034) (Fig. 1).
Pain relief
The changes in VAS scores with salvage chemotherapy are
shown in Fig. 2. At the start of LD-GP therapy, patients
complained of abdominal or back pain, with median (IQR)
VAS scores of 4 (3–6), due to local and/or metastatic UC. In
the other regimens group as well, VAS scores were 4 (3–5),
indicating no significant difference between the two groups
at the start of treatment (p = 0.743). In addition, all patients
in both groups needed analgesic agents. After chemother-
apy, VAS scores in the LD-GP group and other regimens
group were 2 (1–3) and 4 (2–5), respectively, indicating a
significant difference in VAS scores after therapy between
the two groups (p = 0.024). In addition, in the LD-GP
group, VAS scores after therapy significantly decreased
(p \ 0.001) compared to their pretreatment levels (Fig. 2a).
The change in the other regimens group was, however, not
statistically significant (Fig. 2b, p = 0.208).
Changes in VAS scores and analgesic requirements after
therapy in the two groups are shown in Table 3. Improved
pain scores were seen in 24 patients (68.6 %), and decrease
in analgesic consumption was seen in 12 patients (34.3 %)
in the LD-GP group. Of the 24 patients with improved pain
intensity, 8 patients (22.9 %) had improved pain intensity
despite decreasing the dose of analgesic. Finally, positive
pain relief, that is, a decrease in analgesic consumption or a
decrease in VAS scores without increasing the dose of
analgesics, was seen in 28 of the 35 patients who received
LD-GP therapy (80.0 %). Pain control could not be
achieved despite increasing the analgesic dose in only two
patients (5.7 %) in the LD-GP group in our study popula-
tion. On the other hand, in the other regimens group, only
seven of 23 patients (30.4 %) were judged as having
positive pain relief.
Toxicity
The regimen-related toxicities observed during the study
are listed in Table 4. Common myelosuppression-related
toxicities included leukopenia and thrombocytopenia, with
five patients (14.3 %) requiring treatment with granular
colony-stimulating factor (GCSF). In addition, severe
thrombocytopenia occurred in two patients (5.7 %), both of
whom required platelet transfusions; however, no bleeding
episodes occurred.







Complete response 0 (0.0) 1 (4.3) 0.220
Partial response 9 (25.7) 3 (13.0)
Stable disease 22 (62.9) 13 (56.5)
Progressive disease 4 (11.4) 6 (26.1)
LD-GP low-dose combined therapy of gemcitabine and paclitaxel
Fig. 1 Kaplan–Meier survival curves showed that patients who
received LD-GP therapy had a better prognosis compared to those
who received other therapeutic regimens (log-rank p = 0.034). The
other regimens included a combination of paclitaxel and carboplatin,
n = 9; gemcitabine alone, n = 7; combination of gemcitabine and
cisplatin, n = 3; paclitaxel alone, n = 2; and gemcitabine and
carboplatin, n = 2
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The most common non-hematologic toxicity in the
LD-GP group was fatigue (n = 7, 17.1 %), although this
was not severe in any of the patients. Severe non-hemato-
logic toxicity was found in two patients (5.7 %). One patient
showed severe skin rash, which was, however, deemed by
a dermatologist as having no correlation with the treatment
regimen, based on professional examinations including
a drug-induced lymphocyte stimulation (DLST) test.
Although treatment-related pneumonitis was suspected in
two patients, they were diagnosed as having cancer-related
carcinomatous lymphangiomatosis by a chest physician.
None of the patients exhibited a hypersensitivity reaction. In
this study, LD-GP therapy had to be discontinued in two
patients (5.7 %) because of severe drug-related leukopenia
or vomiting. In addition, the GEM and PTX dosages were
reduced to 600 and 60 mg/m2, respectively, in another two
patients (5.7 %) with severe leukopenia. Finally, none of the
patients had fatal complications related to the treatment.
Discussion
CDDP-based combination chemotherapies, such as MVAC
and GC therapy, have been extensively studied in patients
with advanced UC, with general agreement that they are
standard treatments. These therapies improved patient
prognosis compared with other single-agent therapy avail-
able at the time. Unfortunately, however, these CDDP-based
combination chemotherapies were usually not given for long
enough to achieve full efficacy, so that the 50 % survival
periods were less than 2 years [3]. After 2000, although the
GC regimen replaced the MVAC regimen for advanced UC,
because of its lower toxicity, its anti-tumoral effect was
similar to the MVAC regimen [4]. On the other hand,
patients with advanced UC who have recurrent and/or met-
astatic tumors after first-line therapy inherently have an
extremely poor prognosis. Various chemotherapies have
been tried as second- or third-line chemotherapy in patients
with advanced UC who had received prior cisplatin-based
therapy. Patients receiving a combination therapy of PTX,
ifosfamide, and nedaplatin showed a high response rate
Fig. 2 Changes in visual analog scale (VAS) scores after therapy
with a low-dose combination of gemcitabine and paclitaxel (LD-GP)
(a) and other treatment regimens (b). VAS scores decreased
significantly in the LD-GP therapy group (a, p \ 0.001). Although
a similar trend was also found in the other regimens group, the change
was not statistically significant (b, p = 0.208)
Table 3 Changes in visual analog scale scores and analgesic consumption in the two groups







Analgesics consumption n (%)
Decrease 12 (34.3) 8 (22.9 %) 4 (11.4 %) 0 (0.0 %)
No change 21 (60.0) 16 (45.7 %) 5 (14.3 %) 0 (0.0 %)
Increase 2 (5.7) 0 (0.0 %) 0 (0.0 %) 2 (5.7 %)







Analgesics consumption n (%)
Decrease 4 (17.4) 2 (8.7 %) 2 (8.7 %) 0 (0.0 %)
No change 13 (56.5) 3 (13.0 %) 8 (34.8 %) 1 (4.3 %)
Increase 6 (26.1) 6 (26.1 %) 3 (13.0 %) 2 (8.7 %)
LD-GP low-dose combined therapy of gemcitabine and paclitaxel
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(75 %) and relatively long survival (the 1- and 2-year sur-
vival rates were 53.7 and 42.9 %, respectively) [22]. How-
ever, all patients who received this therapy had severe
(Grade 3 and 4) granulocytopenia, and 25 % of them also
had severe thrombocytopenia. In another study, GC therapy
was administered as second-line therapy to 33 patients with
advanced UC after failure of MVAC therapy [23]. This study
showed a response rate of 39.4 % and a 1-year survival rate
of 45.6 %. However, this regimen also showed a relatively
high frequency of toxicities. Conversely, both GEM and
PTX have been reported to be relatively safe and well tol-
erated in advanced cancer patients. Unfortunately, however,
neither of these drugs given as a single agent showed satis-
factory efficacy in inhibiting tumor progression and pro-
longing survival in UC patients with resistance to CDDP-
containing therapy. For example, the response rate to a sin-
gle-agent GEM dose of 1,250 mg/m2 given on days 1 and 8
of a 3-week cycle was 11 % and to a single-agent paclitaxel
dose of 200 mg on day 1 of a 3-week cycle was approxi-
mately 7 % [8, 9]. Many investigators have reported varying
responses to various doses and schedules of GP therapy.
Our regimen has several unique differences compared to
other GP therapy schedules (Table 5). In our study, doses
of GEM and PTX were lowest among all previous reports
regarding the use of GP regimens in advanced UC after
failure of CDDP-containing chemotherapy. In addition,
PTX was administered on day 1 and 8, at the same time as
administration of GEM. Various GEM and PTX regimens
have been described in previous reports. The most repre-
sentative and common regimen is administration of GEM
on day 1, 8, and 15 and PTX on day 1 [11, 15, 17, 18]. In
another report, the day 15 GEM dose was omitted in 31 % of
courses, almost always due to myelosuppression [11]. Our
previous experience using GP therapy, with 1,000 mg/m2
GEM and 150 mg/m2 PTX, also showed similar results (data
not shown). In addition, it has also been suggested that
omission of the day 15 dose may minimize myelosuppres-
sion. Hence, in this study, we omitted the day 15 GP dose.
In regard to the dose–response relationship of PTX, one
study states that a single application is superior to split doses
[14]. In fact, a dose of 80 mg/m2 of PTX in a weekly schedule
produced only 10 % overall response (CR ? PD ? SD).
Our regimen included a lower dose of PTX (60–70 mg/m2).
On the other hand, in almost all GP regimens given as salvage
chemotherapy, PTX was administered only on day 1. In
another regimen in which both GEM (1,000 mg/m2) and
PTX (110 mg/m2) were administered on day 1, 8, and 15, 25
of 36 patients (69.4 %) had a major response to treatment,
including 15 patients (41.7 %) with CR [12]. This regimen is
reportedly one of the most effective GP regimens described
(Table 5). However, patients receiving this regimen were
prone to pulmonary toxicity (4 of 24 patients, 16.7 %).
Hence, the authors decreased the GEM dose to 800 mg/m2
and PTX to 90 mg/m2.
Unfortunately, none of the currently available chemo-
therapeutic agents, including molecular targeted therapy,
have proved successful in improving the long-term survival
of advanced UC patients after failure of previous chemo-
therapy. Hence, the most important criteria for salvage
chemotherapy for advanced UC are safety, lower drug
toxicities, maintenance of patient QOL, and avoidance of
hospitalization whenever possible. Keeping this in mind,
we planned our current regimen of low-dose combination
chemotherapy with GEM and PTX, aiming to prevent
disease progression rather than bringing about a cure, with
maintenance of QOL. Our regimen was successful in
reducing the frequency of severe leukocytopenia and
thrombocytopenia, these being less common in our study
than with previously used GP regimens. In addition, none
of our patients developed severe pulmonary toxicity, neu-
ropathy, or hypersensitivity. Thus, as we expected, LD-GP
therapy has the potential to be well tolerated as salvage
chemotherapy with minimum adverse events.
At the start of this study, we did not expect a marked
response to LD-GP therapy and just hoped to lessen the
momentum and velocity of tumor growth and progression.
However, although none of the patients in our study had
CR with LD-GP and the major response (CR ? PR) rate
was the lowest (25.7 %) among all previous reports, sur-
prisingly, the median survival was relatively long, beyond
our expectations, and longer than the survival times
described in other similar reports. For example, the 1-year
survival rate in our study was similar to other GP regimens
that used high doses of GEM and PTX in advanced UC
patients who had previously received platinum-based che-
motherapy regimens (57 %) [11]. We are unable to explain
the reasons for this favorable phenomenon observed in the
present study. However, it is possible that maintenance of
QOL and avoidance of the side effects of analgesic drugs
may have contributed to the relatively long survival, since
nutritional status and physical activity are important
Table 4 Common treatment-related toxicities in the LD-GP group
Incidence n (%)
Total Grade 3 ? 4
Myelosuppression-related
Anemia 6 (17.1) 2 (5.7)
Leukopenia 9 (25.7) 5 (14.3)
Thrombocytopenia 8 (22.9) 2 (5.7)
Non-hemorrhagic complications
Fatigue 6 (17.1) 0 (0.0)
Nausea/vomiting 4 (11.4) 1 (2.9)
Peripheral neuropathy 4 (11.4) 0 (0.0)
Skin rash 2 (5.7) 1 (2.9)
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effectors of survival in various advanced cancers [24, 25].
In particular, avoidance of severe toxicities may be bene-
ficial in improving the survival in advanced UC patients
after failure of previous treatments. From these facts, we
speculated that LD-GP therapy affected survival through
inhibition of tumor progression and improvement of the
patients’ general physical status.
One of the interesting findings of the present study
is that LD-GP therapy improved pain relief in
advanced UC patients with resistance to CDDP-containing




(mg/m2; day) (every weeks)




2001 [10] 41 2,500–3,000; 1
150; 1
(2)
27.5/32.5 NS/NS 14.4 31.7/0.0
2001 [11] 15 1,000; 1, 8, 15
200; 1
(3)
6.7/40.0 NS/NS NS NS/NS
2005 [12] 36 1,000; 1, 8, 15
110; 1, 8, 15
(4)
41.7/27.8 NS/NS 15.3 36.1/8.3
2006 [13] 23 2,500; 1
150; 1
(2)
0.0/30.4 NS/NS 12.1 26.1/NS
2006 [14] 14 1,000; 1, 8
175; 1
(3)




7.7/30.8 NS/NS 9 23.1/15.4
2007 [15] 10 1,000; 1, 8, 15
200; 1
(3)
20.0/50.0 40/NS 10.3 50.0/10.0
2008 [16] 20 2,500; 1
150; 1
(2/3)
5.0/25.0 35/NS 11.5 30.0/5.0
2009 [17] 33 1,000; 1, 8, 15
180; 1
(4)
3.0/0.0 NS/NS 11.3 18.2/NS
2011 [18] 24 1,000; 1, 8, 15
200; 1
(3)
8.3/33.3 52/11 12.4 66.7/4.2
2011 [19] 48 1,000; 1, 8
175; 1
(3a)




14.6/26.8 NS/NS 8.0 NS/NS
This study 35 700; 1, 8
70; 1, 8
(4)
0.0/25.7 58.1/32.9 12.0 14.3/8.6
NS not shown, SR survival rate, yr year, mos months
a A maximum of 6 cycles; b Given until disease progression
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chemotherapy. Actually, 24 of the 35 patients had
decreased VAS scores after LD-GP therapy. In addition, a
decrease in analgesic consumption was found in approxi-
mately one-third of our patients, and a quarter of them had
improved pain relief despite a decrease in analgesic con-
sumption. In a previous report on other cancers, three
cycles of gemcitabine (1 g/m2 on day 1, 8, and 15) pro-
duced complete relief of pain in all of the four patients with
advanced biliary tract cancer studied [26]. In addition,
GEM, administered as a single agent, has been reported to
reduce pain in patients with CDDP refractory UC [8].
Weekly paclitaxel also reportedly reduced moderate to
severe pain (VAS scores 3–8) from 35.1 to 24.3 % in 37
patients with advanced non-small cell lung cancer [20].
Thus, both GEM and PTX may have some palliative effects
on tumor-associated pain. However, we did not observe
such phenomena in the other GEM-based and PTX-based
regimens administered in this study. Even if these drugs do
have significant pain-relieving effects, rapid growth and
progression of the tumor may offset them. Furthermore, in
the presence of other severe complications, patients are
unable to appreciate the pain relief. Based on these facts,
we speculated that LD-GP therapy results in an optimal
balance between anti-tumoral effects and minimal
adverse effects, allowing the patient to appreciate the pain
relief.
Further follow-up is necessary to definitively prove the
survival benefit of the LD-GP regimen, because the median
follow-up period of patients receiving LD-GP therapy in
this study was only 10 months and our study population
was small. In addition, this study was not a prospective
randomized study. Hence, more detailed and larger studies
are necessary to decisively conclude about the anti-tumoral
effects, including pain control, patient survival, and tox-
icities of LD-GP therapy. In our opinion, however, LD-GP
therapy is feasible and well tolerated as second- or third-
line chemotherapy in patients with advanced UC.
Conclusion
The results of this study demonstrated that LD-GP therapy
has anti-tumoral effects in advanced UC patients with
resistance to CDDP-containing therapy. In particular, this
regimen is useful for pain relief in these patients. The
common toxicity associated with the LD-GP therapy in this
study was leukopenia, and the most common non-hema-
tologic toxicity was fatigue. However, the frequency and
severity of toxicities with the LD-GP regimen used in this
study were lower than those with other GP regimes. We
speculate that LD-GP therapy is feasible and well tolerated
as salvage therapy in patients with advanced UC with
resistance to CDDP-containing therapy.
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